TUMOR MARKERS IN DIAGNOSIS AND SCREENING

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

TUMOR MARKERS IN DIAGNOSIS AND SCREENING

Int Congr Ser; 807:3-16 1989. Unique Identifier : AIDSLINE ICDB/90657991
Schwartz MK; Dept. of Clinical Chemistry, Memorial Sloan-Kettering Cancer; Center, 1275 York Ave., New York, NY 10021

Abstract: A wide variety of substances can be identified as tumor markers. These include tumor-associated antigens, enzymes, specific proteins, and metabolites. Tumor markers employed in screening for cancer in general and in diagnosis and management of germ cell tumors and ovarian, colorectal, lung, breast, and prostate cancers are reviewed. Among the tumor markers and putative tumor markers considered are alpha-fetoprotein, carcinoembryonic antigen, vanillylmandelic acid, chorionic gonadotropin, CA-125, CA-19-9, ferritin, sialic acids, neuron specific enolase, CA-15-3, phosphohexose isomerase, and prostate-specific antigen. Measurement of tumor markers has been suggested for screening both total populations and high-risk groups. Markers are used in diagnosis either as aids in staging or in confirmation of histopathology. Tumor markers also have been used in therapy to predict drug response and prognosis and to follow the course of the disease. Circulating tumor markers have an important role in the management of patients with breast, lung, ovary, and prostate cancers. The need for the future is to identify patients who are at high risk for cancer. Analysis of oncogenes may play this role when the technology becomes more suitable for mass clinical application. (22 Refs)

Keywords: Animal Antigens, Neoplasm/ANALYSIS Breast Neoplasms/PREVENTION & CONTROL Colorectal Neoplasms/PREVENTION & CONTROL Cross-Sectional Studies Female Human Lung Neoplasms/PREVENTION & CONTROL Male *Mass Screening Neoplasm Proteins/ANALYSIS Neoplasms/DIAGNOSIS/*PREVENTION & CONTROL Neoplasms, Germ Cell and Embryonal/PREVENTION & CONTROL Oncogenes Ovarian Neoplasms/PREVENTION & CONTROL Prostatic Neoplasms/PREVENTION & CONTROL Risk Factors Tumor Markers, Biological/*ANALYSIS JOURNAL ARTICLE REVIEW
912130
M91C4114

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .